These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 32501032

  • 1. Perspectives and practices of ototoxicity monitoring.
    Paken J, Govender CD, Pillay M, Sewram V.
    S Afr J Commun Disord; 2020 May 19; 67(1):e1-e10. PubMed ID: 32501032
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting.
    Paken J, Govender CD, Pillay M, Sewram V.
    BMC Health Serv Res; 2022 Jun 18; 22(1):791. PubMed ID: 35717191
    [Abstract] [Full Text] [Related]

  • 3. Research protocol: Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program.
    Paken J, Govender CD, Sewram V.
    BMC Womens Health; 2017 Dec 11; 17(1):129. PubMed ID: 29228931
    [Abstract] [Full Text] [Related]

  • 4. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
    Paken J, Govender CD, Pillay M, Ayele BT, Sewram V.
    BMC Cancer; 2021 Jul 16; 21(1):822. PubMed ID: 34271863
    [Abstract] [Full Text] [Related]

  • 5. Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity.
    Paken J, Govender CD, Pillay M, Ayele BT, Sewram V.
    BMC Womens Health; 2021 Apr 20; 21(1):164. PubMed ID: 33879158
    [Abstract] [Full Text] [Related]

  • 6. Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology.
    Garinis AC, Cornell A, Allada G, Fennelly KP, Maggiore RJ, Konrad-Martin D.
    Int J Audiol; 2018 Sep 20; 57(sup4):S19-S24. PubMed ID: 28978238
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
    Paken J, Govender CD, Pillay M, Feyasa M, Sewram V.
    PLoS One; 2023 Sep 20; 18(4):e0283639. PubMed ID: 37014872
    [Abstract] [Full Text] [Related]

  • 8. Ototoxicity management: An investigation into doctors' knowledge and practices, and the roles of audiologists in a tertiary hospital.
    Wium A, Gerber B.
    S Afr J Commun Disord; 2016 Dec 01; 63(1):e1-e15. PubMed ID: 28155308
    [Abstract] [Full Text] [Related]

  • 9. The current state of ototoxicity monitoring in New Zealand.
    Steffens L, Venter K, O'Beirne GA, Kelly-Campbell R, Gibbs D, Bird P.
    N Z Med J; 2014 Jul 18; 127(1398):84-97. PubMed ID: 25146864
    [Abstract] [Full Text] [Related]

  • 10. What Are the Current Audiological Practices for Ototoxicity Assessment and Management in the South African Healthcare Context?
    Khoza-Shangase K, Masondo N.
    Int J Environ Res Public Health; 2020 Apr 10; 17(7):. PubMed ID: 32290287
    [Abstract] [Full Text] [Related]

  • 11. Practice of Monitoring Cisplatin-Induced Ototoxicity by Audiology, ENT, and Oncology Specialists: A Survey-Based Study in a Single Italian Medical Center.
    Gambacorta V, Orzan E, Faralli M, Gullà M, Lapenna R, Baietta I, De Angelis V, Ricci G.
    Audiol Res; 2023 Oct 18; 13(5):779-790. PubMed ID: 37887850
    [Abstract] [Full Text] [Related]

  • 12. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2014 Jul 01; (7):CD009219. PubMed ID: 24984156
    [Abstract] [Full Text] [Related]

  • 13. High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa.
    Whitehorn H, Sibanda M, Lacerda M, Spracklen T, Ramma L, Dalvie S, Ramesar R.
    S Afr Med J; 2014 Apr 01; 104(4):288-91. PubMed ID: 25118554
    [Abstract] [Full Text] [Related]

  • 14. Audiologists' perceived value of ototoxicity management and barriers to implementation for at-risk cancer patients in VA: the OtoMIC survey.
    Konrad-Martin D, Polaski R, DeBacker JR, Theodoroff SM, Garinis A, Lacey C, Johansson K, Mannino R, Milnes T, Hungerford M, Clark KD.
    J Cancer Surviv; 2023 Feb 01; 17(1):69-81. PubMed ID: 36729345
    [Abstract] [Full Text] [Related]

  • 15. A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients.
    Konrad-Martin D, O'Connell Bennett K, Garinis A, McMillan GP.
    Am J Audiol; 2021 Oct 11; 30(3S):870-886. PubMed ID: 34582263
    [Abstract] [Full Text] [Related]

  • 16. Ototoxicity monitoring in South African cancer facilities: A national survey.
    Ehlert K, Heinze B, Swanepoel W.
    S Afr J Commun Disord; 2022 Jan 19; 69(1):e1-e10. PubMed ID: 35144440
    [Abstract] [Full Text] [Related]

  • 17. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD009219. PubMed ID: 22592737
    [Abstract] [Full Text] [Related]

  • 18. Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
    Moore B, Sheets G, Doss J, Umrigar A, Norman M, Fang Z, Prasad P, Musso A, Clay S, Tsien F.
    Am J Audiol; 2023 Sep 06; 32(3):657-664. PubMed ID: 37532243
    [Abstract] [Full Text] [Related]

  • 19. Challenges in ototoxicity monitoring in the pediatric oncology population.
    Bass JK, Bhagat SP.
    J Am Acad Audiol; 2014 Sep 06; 25(8):760-74; quiz 782-3. PubMed ID: 25380122
    [Abstract] [Full Text] [Related]

  • 20. Public awareness of audiology, hearing and hearing health in the Limpopo Province, South Africa.
    Joubert K, Sebothoma B, Kgare KS.
    S Afr J Commun Disord; 2017 Sep 28; 64(1):e1-e9. PubMed ID: 29041791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.